Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Other Non-Current Liabilities (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $336000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 67.69% to $336000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $336000.0, a 67.69% decrease, with the full-year FY2024 number at $565000.0, up 37.14% from a year prior.
  • Other Non-Current Liabilities was $336000.0 for Q3 2025 at Mereo BioPharma, down from $352000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.8 million in Q4 2021 to a low of $37000.0 in Q1 2024.
  • A 4-year average of $544930.4 and a median of $352000.0 in 2025 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 97.35% in 2021, then soared 778.38% in 2025.
  • Mereo BioPharma's Other Non-Current Liabilities stood at $1.8 million in 2021, then tumbled by 76.85% to $412000.0 in 2023, then skyrocketed by 37.14% to $565000.0 in 2024, then tumbled by 40.53% to $336000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Other Non-Current Liabilities are $336000.0 (Q3 2025), $352000.0 (Q2 2025), and $325000.0 (Q1 2025).